Nec Corporation

Kyowa Hakko Kirin Co., Limited

Renesas Electronics Corporation

Sharp Kabushiki Kaisha Corporation

International Business Machines Corporation

Sanyo Electric Co., Ltd.

Sumitomo Metal Industries, Inc.

Konica-Minolta Holdings, Inc.

Nec Electronics Corporation

Yanmar Co., Ltd.

Konica Minolta, Inc.

Tokyo Electron Limited

Nippon Steel Sumitomo Metal Corporation

Osaka University

Nippon Steel Corporation

Nobuaki Takahashi

Naoji Senba

Koji Soejima

Masaya Kawano

Yuzo Shimada

Masahiro Komuro

Akio Yamamoto

Ryosuke Nakano

Sayaka Maeda

Toru Miura

Seiji Munetoh

Hideaki Yoshida

Hideto Niijima

Yuji Ito

Satoshi Matsui

Masahiko Hamada

Hiroki Murata

Yoshinori Kitagawa

Masahiro Imai

Toshifumi Mikayama

Aki Matsushima

Yozo Oka

Xingjie Chen

Shinichi Miyazaki

Hitoshi Yoshida

Noboru Yamamoto

Shigetoshi Kawabe

Kazuyoshi Yoshimi

Kazumasa Kamatani

Akira Murakami

Takumi Ishiwata

Yuji Kan

Atsushi Okuda

Katsumasa Hashimoto

Yoshitaka Kyougoku

Tomoaki Ikeda

Souji Sakata

Yoshitsugu Kawahigashi

Koichi Yoshioka

Walker R Force

Yoichiro Kurita

Kenji Arai

Gaku Yamamoto

Nobuyuki Ohba

Yusuke Mori

Takeshi Hakii

Yuji Akimoto

Hikaru Kouta

Akihiro Iwamatsu

Rinpei Niwa

Mikio Oda

Masayuki Imanishi

Saburou Hiraoka

Natsuki Yamamoto

Akihiro Yamanaka

Shingo Nagai

Takeo Nakada

Shuh Narumiya

Atsushi Nishizawa

Teruo Kusaka

Kazuhiko Futakami

Hidetsugu Kawamori

Koji Neishi

Masaaki Murayama

Fumitomo Ohsawa

Yoshihiro Uda

Atsuo Hamada

Hiroaki Yamagishi

Shuji Okaguchi

Takenao Yamada

Naoki Suetsugu

Ryuji Katayama

Yoshitoshi Morita

Hidetoshi Fukuoka

Kozo Kaibuchi

Yoshinobu Tomomura

Tahei Nakaue

Masayuki Kai

Stephen P Schoenberger

Toshiyuki Shin

Tetsuya Fukuba

Shigemichi Yamauchi

Daisuke Numakura

Atuo Hamada

Naoki Suetugu

Syuzo Ueyama

Shinji Murabe

Seiji Maeda

Takumi Yamamoto

Aki Hirano

Akira Hatase

Norihisa Shintani

Syuzou Ueyama

Kohei Kitagawa

Mitsuru Nagano

Ichirou Seta

Hideo Touge

Osamu Shibazaki

Masaaki Ito

Takeshi Nakano

The invention relates to an antibody which binds to myelin oligodendrocyte glycoprotein (MOG), an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment, a nucleic acid containing a nucleotide sequence which encodes the antibody or the antibody fragment, a transformant cell containing a vector containing the nucleic acid, a method for producing the antibody or the antibody fragment, a composition containing the antibody or the antibody fragment and a method for detecting or measuring an antigen that is present in the brain, a method for diagnosing or treating a brain disease, a method for improving the property of an antibody of accumulating in the brain and a method for increasing the amount of an antibody in the brain which use the antibody or the antibody fragment.

Antibody which binds to myelin oligodendrocyte glycoprotein

The present invention relates to a bispecific antibody in which an N-terminal side polypeptide is bound to an IgG portion that binds to TfR, a bispecific antibody fragment thereof, a DNA encoding the bispecific antibody or the bispecific antibody fragment thereof, a vector containing the DNA, a hybridoma and a transformant that produce the bispecific antibody or the bispecific antibody fragment thereof, a method for producing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic agents containing the bispecific antibody or the bispecific antibody fragment thereof, therapeutic and diagnostic methods using the bispecific antibody or the bispecific antibody fragment thereof, and a reagent for detection or measurement containing the bispecific antibody or the bispecific antibody fragment thereof.

Bispecific antibody binding to TfR

The method of forming a nitride semiconductor film includes intermittently sputtering a target of gallium nitride inside a vacuum chamber containing nitrogen and argon, and depositing sputtered particles of the gallium nitride that are scattered from the target inside the vacuum chamber, on a substrate having a temperature of 560 degrees C. or higher and 650 degrees C. or lower. A ratio of a flow rate of the nitrogen to a sum of the flow rate of the nitrogen and a flow rate of the argon supplied to the vacuum chamber is 6% or higher and 18% or lower.

Method of forming nitride semiconductor film

The invention relates to an antibody which binds to chondroitin sulfate proteoglycan 5 (CSPG5) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.

Antibody binding to chondroitin sulfate proteoglycan 5

A tag indicating an attribute of the tag by an electromagnetic wave reflection characteristic, the tag including a substrate (), and a conductor pattern layer () formed on the substrate () and having first and second slots () and () disposed adjacent to each other, in which the first slot () constitutes a first resonance element (Qa) having a resonance frequency at a first frequency, the second slot () constitutes a second resonance element (Qb) having a resonance frequency at a second frequency higher than the first frequency, and when irradiation with the electromagnetic waves is performed, a Q value of a resonance peak appearing at the first frequency is higher than a Q value of a resonance peak appearing at the first frequency when the first slot () alone constitutes a resonance structure of the tag.

The invention relates to an antibody which binds to cell adhesion molecule 3 (CADM3) or an antibody fragment thereof, a hybridoma which produces the antibody or the antibody fragment thereof, a nucleic acid comprising a nucleotide sequence encoding the antibody or the antibody fragment thereof, a transformant cell comprising a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof, a composition comprising the antibody or the antibody fragment thereof, and a method for detecting or measuring an antigen present in the brain, a method for diagnosing or treating a brain disease, a method for enhancing the property of accumulating in a brain of an antibody, and a method for increasing the amount of an antibody in the brain, each of which using the antibody or the antibody fragment thereof, and the like.

Antibody binding to cell adhesion molecule 3

An object of the present invention is to provide a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to an epithelial cell adhesion molecule (EpCAM). The present invention relates to a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to EpCAM.

Bispecific antibody which binds to CD40 and EpCAM

A detecting system includes: a sensor () that includes an antenna unit () formed with a metal pattern, and a back surface reflector () that faces the antenna unit () via an isolation layer (); and a reader () that transmits electromagnetic waves (Fa) to the sensor (), receives reflected waves (Fr) from the sensor (), and compares the reflection characteristics of the sensor () detected from the reflected waves (Fr) with the reflection characteristics of the sensor () stored in advance, to detect a state change in the sensor ().

Detecting system, and reader

A method distributes and manages medical information on a communication network over a wide area. Encrypted medical information is acquired from one of a plurality of first computers by a second computer connected to the communication network, the plurality of first computers being connected to the communication network, holding identical medical information, encrypting medical information, and sending and receiving encrypted medical information. The second computer decrypts the acquired encrypted medical information, browses and updates decrypted medical information, and then encrypts the browsed and updated medical information. The second computer then sends the encrypted browsed and updated medical information to the plurality of first computers.

Data management mechanism for wide-area distributed medical information network

It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.

Methods for producing stabilized human IgG2 and IgG3 antibodies

The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof.

Stable multivalent antibody

A highly stable mutant of human IgG4 antibody is provided. Such antibody is an antibody in which the CH3 domain of human IgG4 is substituted with the CH3 domain of human IgG1 and which exhibits inhibited aggregate formation, an antibody in which the CH3 and CH2 domains of human IgG4 are substituted with the CH3 and CH2 domains of human IgG1, respectively, or an antibody in which arginine at position 409 indicated in the EU index proposed by Kabat et al. of human IgG4 is substituted with lysine and which exhibits inhibited aggregate formation.

Stabilized human IgG4 antibodies

A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.

Anti-CD40 antibody mutants

A high-strength steel sheet having improved HIC resistance and fracture resistance even when it is thick has a chemical composition comprising, in mass %, C: 0.02-0.07%, Si: 0.05-0.50%, Mn: 1.10-1.60%, P: at most 0.015%, S: at most 0.0030%, Nb: 0.005-0.030%, Ti: 0.005-0.020%, Al: 0.005-0.060%, Ca: 0.0005-0.0060%, N: 0.0015-0.0070%, at least one of Cu, Ni, Cr, and Mo in a total of greater than 0.1% to less than 1.5%, and a remainder of Fe and impurities and a steel structure composed of at least 10% by area of bainite and a remainder of ferrite and pearlite. The degree of segregation is less than 1.6 for Nb and less than 1.4 for Mn in the central portion of the thickness of the steel sheet.

High-strength steel sheet having improved resistance to fracture and to HIC

Growing community of inventors

Tokyo, Japan

Nobuaki Takahashi